선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
Veralto Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $23.3B | |
|---|---|---|
| Revenue (ttm) | 5.7B | |
| Net income (ttm) | 988M | |
| EPS (ttm) | $3.97 | |
| Shares out | 243.8M | |
| P/E (trailing) | 25.9x | |
| P/E (forward) | 20.0x | |
| Dividend | $0.52 (0.51%) | |
| Volume | 2,001,839 | |
| Beta | 0.77 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $4.70B | $4.87B | $5.02B | $5.19B | $5.50B | +4.0% |
| Gross profit | $2.71B | $2.76B | $2.90B | $3.11B | $3.30B | +5.0% |
| Operating income | $1.04B | $1.11B | $1.14B | $1.21B | $1.28B | +5.2% |
| Net income | $861.0M | $845.0M | $839.0M | $833.0M | $940.0M | +2.2% |
| EPS (diluted) | $3.50 | $3.43 | $3.40 | $3.34 | $3.76 | +1.8% |
| EBITDA | $1.15B | $1.20B | $1.21B | $1.28B | $1.35B | +4.1% |
| R&D | $244.0M | $217.0M | $225.0M | $253.0M | $266.0M | +2.2% |
| SG&A | $1.43B | $1.43B | $1.54B | $1.64B | $1.76B | +5.3% |
Recent company headlines from major financial publishers.
The Base scenario establishes Fair value at $79.82, implying a return of -16.4% at a probability of 60.0%. In this modal path, Veralto executes its compounder playbook with mid-single-digit revenue growth driven by the mission-critical replacement of testing consumables, proprietary reagents, and marking inks. Operating margins expand moderately as standalone public company overhead rationalizes and pricing power outpaces input inflation. The business generates exceptional free cash flow conversion on minimal capital expenditure requirements. However, because $95.44 already trades at an elevated forward earnings multiple above peer medians, total returns are restrained by multiple compression toward historical norms. Disconfirmation would occur if organic growth slips below nominal economic growth or if operating margins fail to improve over the FY2026 to FY2027 forecast period.
Under the Bull scenario, with Potential value of $94.43 representing a return of -1.1% at a probability of 20.0%, statutory water quality mandates accelerate globally. Tightening environmental standards for PFAS and micro-pollutants drive double-digit growth in analytical instrumentation and recurring consumable reagents across municipal utilities. Meanwhile, industrial water reuse investments surge and Product and Quality Innovation benefits from stringent pharmaceutical and packaging traceability regulations. Operating leverage through the Veralto Business System expands operating margins beyond historical highs, and disciplined bolt-on acquisitions in water analytics software accelerate earnings growth. This scenario would be disconfirmed if municipal infrastructure disbursements stall or if operating margin expansion plateaus before the conclusion of FY2027.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 6.9% | $87.8 | $90.8 | $94.1 | $97.9 | $102 |
| 7.4% | $81.2 | $83.6 | $86.2 | $89.2 | $92.4 |
| 7.9% | $75.8 | $77.7 | $79.8 | $82.2 | $84.7 |
| 8.4% | $71.2 | $72.8 | $74.5 | $76.4 | $78.5 |
| 8.9% | $67.2 | $68.6 | $70.0 | $71.6 | $73.3 |
Upcoming earnings date and setup when available.
매월 발행된 리서치 판이 부여한 등급입니다. 등급은 분석 시점의 가격을 공정 가치와 비교한 것이며, 판단이 맞았는지에 대한 기록이 아닙니다.
| 연도 | 1월 | 2월 | 3월 | 4월 | 5월 | 6월 | 7월 | 8월 | 9월 | 10월 | 11월 | 12월 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |